Although IL-23 inhibition has been proven to be an effective mechanism in the treatment of IBD in clinical trials, there is no evidence that IL-17 inhibition provides any benefits; instead, it is associated with an increase in AEs. This evidence concerns the gene IL17A and irritable bowel syndrome.